Menu
Search
|

Menu

Close
X

Takeda Pharmaceutical Co Ltd 4502.T (Tokyo Stock Exchange)

3,788.00 JPY
+2.00 (+0.05%)
As of 2:00 AM EDT
Previous Close 3,786.00
Open 3,780.00
Volume 4,598,700
3m Avg Volume 5,238,865
Today’s High 3,797.00
Today’s Low 3,757.00
52 Week High 4,943.00
52 Week Low 3,401.00
Shares Outstanding (mil) 1,576.36
Market Capitalization (mil) 5,755,279.00
Forward P/E 21.24
Dividend (Yield %) 90.00 ( 4.93 )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.82 Mean rating from 11 analysts

KEY STATS

Revenue (mm, JPY)
FY19
2,097,224
FY18
1,770,531
FY17
1,732,050
FY16
1,807,378
EPS (JPY)
FY19
171.880
FY18
237.491
FY17
146.104
FY16
101.109
*Note: Units in Millions of Yen
**Note: Units in Yen

KEY RATIOS

Price to Earnings (TTM)
vs sector
21.24
33.85
Price to Sales (TTM)
vs sector
2.74
7.90
Price to Book (MRQ)
vs sector
1.10
4.38
Price to Cash Flow (TTM)
vs sector
15.09
23.70
Total Debt to Equity (MRQ)
vs sector
111.46
17.64
LT Debt to Equity (MRQ)
vs sector
92.37
12.61
Return on Investment (TTM)
vs sector
1.48
12.69
Return on Equity (TTM)
vs sector
3.05
17.13

EXECUTIVE LEADERSHIP

Masahiro Sakane
Independent Chairman of the Executive Board, Since 2017
Salary: --
Bonus: --
Christophe Weber
President, Chief Executive Officer, Representative Director, Since 2015
Salary: --
Bonus: --
Andrew Plump
Chief Medical & Scientific Officer, Director, Since 2015
Salary: --
Bonus: --
Masato Iwasaki
President of Japan Pharma Business Unit, Director, Since 2015
Salary: --
Bonus: --
Yasuhiko Yamanaka
Director, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

4F, 2-1-1, Nihombashihon-cho
CHUO-KU   TKY   103-8668

Phone: +813.32782111

Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The Company is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.

SPONSORED STORIES